Skip to content

Research at St Andrews

Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation

Research output: Contribution to journalArticlepeer-review


Rebecca H. Chisholm, Tommaso Lorenzi, Jean Clairambault

School/Research organisations


Background. Drug-induced drug resistance in cancer has been attributed to diverse biological mechanisms at the individual cell or cell population scale, relying on stochastically or epigenetically varying expression of phenotypes at the single cell level, and on the adaptability of tumours at the cell population level.
Scope of review. We focus on intra-tumour heterogeneity, namely between-cell variability within cancer cell populations, to account for drug resistance. To shed light on such heterogeneity, we review evolutionary mechanisms that encompass the great evolution that has designed multicellular organisms, as well as smaller windows of evolution on the time scale of human disease. We also present mathematical models used to predict drug resistance in cancer and optimal control methods that can circumvent it in combined therapeutic strategies.
Major conclusions. Plasticity in cancer cells, i.e., partial reversal to a stem-like status in individual cells and resulting adaptability of cancer cell populations, may be viewed as backward evolution making cancer cell populations resistant to drug insult. This reversible plasticity is captured by mathematical models that incorporate between-cell heterogeneity through continuous phenotypic variables. Such models have the benefit of being compatible with optimal control methods for the design of optimised therapeutic protocols involving combinations of cytotoxic and cytostatic treatments with epigenetic drugs and immunotherapies.
General significance. Gathering knowledge from cancer and evolutionary biology with physiologically based mathematical models of cell population dynamics should provide oncologists with a rationale to design optimised therapeutic strategies to circumvent drug resistance, that still remains a major pitfall of cancer therapeutics. This article is part of a Special Issue entitled "System Genetics" Guest Editor: Dr. Yudong Cai and Dr. Tao Huang.


Original languageEnglish
Pages (from-to)2627-2645
Number of pages19
JournalBiochimica et Biophysica Acta - General Subjects
Issue number11, Part B
Early online date20 Jun 2016
Publication statusPublished - Nov 2016

    Research areas

  • Heterogeneity, Cancer cell populations, Evolution, Drug resistance, Cancer therapeutics, Optimal control

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by journal

  1. Albumin research in the 21st century

    Peters Jr, T. & Stewart, A. J., Dec 2013, In: Biochimica et Biophysica Acta - General Subjects. 1830, 12, p. 5351-5353 3 p.

    Research output: Contribution to journalEditorial

  2. Allosteric modulation of zinc speciation by fatty acids

    Barnett, J. P., Blindauer, C. A., Kassaar, O., Khazaipoul, S., Martin, E. M., Sadler, P. J. & Stewart, A. J., Dec 2013, In: Biochimica et Biophysica Acta - General Subjects. 1830, 12, p. 5456-5464 9 p.

    Research output: Contribution to journalArticlepeer-review

  3. The pH-dependent conformational transition of beta-lactoglobulin modulates the binding of protoporphyrin IX

    Tian, F., Johnson, K., Lesar, A. E., Moseley, H., Ferguson, J., Samuel, I. D. W., Mazzini, A. & Brancaleon, L., Jan 2006, In: Biochimica et Biophysica Acta - General Subjects. 1760, p. 38-46 9 p.

    Research output: Contribution to journalArticlepeer-review

  4. Conformational changes in monoamine oxidase A in response to ligand binding or reduction

    Hynson, RMG., Kelly, SM., Price, NC. & Ramsay, R. R., 7 Apr 2004, In: Biochimica et Biophysica Acta - General Subjects. 1672, 1, p. 60-66 7 p.

    Research output: Contribution to journalArticlepeer-review

ID: 243564098